ArticleThe Journal of investigative dermatology2016
Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
Abstract readComparative Study
In one paragraph
Article in The Journal of investigative dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Article
- Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.Cancers · 2023Article
- Association of germline variants in telomere maintenance genes (JAAD international · 2023Article
- Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.Journal of clinical medicine · 2021Review
- FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.Familial cancer · 2021Article
- Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.Journal of the American Academy of Dermatology · 2020Article
- Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.The Journal of investigative dermatology · 2020Article
- Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.Journal of the American Academy of Dermatology · 2019Article
- Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.The Journal of investigative dermatology · 2017Article
- Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.JAMA dermatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Nicholas J TaylorDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Elizabeth A HandorfDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Nandita MitraDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Marie-Françoise AvrilAssistance Publique-Hôpitaux de Paris, Hôpital Cochin et Université Paris Descartes, Paris, France.
Esther AziziDepartment of Dermatology, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Wilma BergmanDepartment of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.
Giovanna Bianchi-ScarràDepartment of Internal Medicine and Medical Specialties, University of Genoa and IRCCS AOU San Martino-IST Genoa, Italy.
D Timothy BishopSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Brigitte Bressac-de PailleretsDepartment of Biopathology and INSERM U1186, Gustave Roussy, Villejuif, France.
Donato CalistaDermatology Unit, Maurizio Bufalini Hospital, Cesena, Italy.
Lisa A Cannon-AlbrightDivision of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Francisco CuellarMelanoma Unit, Dermatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain and CIBER de Enfermedades Raras, Barcelona, Spain.
Anne E CustSydney School of Public Health, University of Sydney, Sydney, NSW, Australia.
Florence DemenaisINSERM, UMR-946, Genetic Variation and Human Disease Unit, Université Paris Diderot, Paris, France.
David E ElderDepartments of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Eitan FriedmanThe Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Anne-Marie GerdesDepartment of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.
Paola GhiorzoDepartment of Internal Medicine and Medical Specialties, University of Genoa and IRCCS AOU San Martino-IST Genoa, Italy.
Alisa M GoldsteinHuman Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Thais C GrazziotinUniversidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre RS, Brazil.
Johan HanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Nicholas K HaywardQIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Marko HocevarInstitute of Oncology Ljubljana, Zaloska, Ljubljana, Slovenia.
Veronica HöiomDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Elizabeth A HollandCentre for Cancer Research, Westmead Institute for Medical Research and Melanoma Institute Australia, University of Sydney, NSW, Australia.
Christian IngvarDepartment of Surgery, Lund University Hospital, Lund, Sweden.
Maria Teresa LandiHuman Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Gilles LandmanDepartment of Pathology, Escola Paulista de Medicina, UNIFESP, São Paulo, Brazil.
Alejandra Larre-BorgesUnidad de Lesiones Pigmentadas, Cátedra de Dermatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.
Sancy A LeachmanOregon Health Sciences University School of Medicine, Department of Dermatology, Portland, Oregon, USA.
Graham J MannCentre for Cancer Research, Westmead Institute for Medical Research and Melanoma Institute Australia, University of Sydney, NSW, Australia.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
Håkan OlssonCentre for Cancer Research, Westmead Institute for Medical Research and Melanoma Institute Australia, University of Sydney, NSW, Australia.
Jane PalmerQIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Barbara PerićInstitute of Oncology Ljubljana, Zaloska, Ljubljana, Slovenia.
Dace PjanovaLatvian Biomedical Research and Study Centre, Riga, Latvia.
Susana PuigMelanoma Unit, Dermatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain and CIBER de Enfermedades Raras, Barcelona, Spain.
Helen SchmidCentre for Cancer Research, Westmead Institute for Medical Research and Melanoma Institute Australia, University of Sydney, NSW, Australia.
Nienke van der StoepDepartment of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.
Margaret A TuckerHuman Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Karin A W WadtDepartment of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.
Linda WhitakerSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Xiaohong R YangHuman Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Julia A Newton BishopSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Nelleke A GruisDepartment of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands.
Peter A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA. Electronic address: peter.kanetsky@moffitt.org.
GenoMEL Consortium
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MGenetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0MMoffitt Postdoctoral Training Program in Molecular & Genetic EpidemiologyR25CA147832 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EGAN, KATHLEEN M. · 2010 to 2014
$2.0MMoffitt Postdoctoral Training Program in Molecular EpidemiologyT32CA147832 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KANETSKY, PETER A · 2015 to 2019
$659kCancer Research UK 10589Cancer Research UK 19167Medical Research Council MR/L01629X/1NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA083115NCI NIH HHS R25 CA147832NCI NIH HHS T32 CA147832
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBiopsy, NeedleCohort StudiesCutaneous Malignant MelanomaCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Databases, FactualFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryIncidenceMaleMelanomaMiddle AgedCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.